Читать книгу Clinical Pharmacology and Therapeutics - Группа авторов - Страница 109

Pregnancy is associated with a 10‐fold increased risk of developing venous thromboembolic disease (VTE) and is the major direct cause of maternal mortality in the UK. Treatment and prophylaxis of VTE requires anticoagulants which have special considerations in pregnancy. Warfarin is teratogenic when given between the sixth and twelfth week of pregnancy – a 5% risk of major abnormality and 0.6% risk of warfarin embryopathy. It is also associated with bleeding during pregnancy and at delivery, and is generally avoided except in very high risk cases. Low molecular weight heparin is usually the treatment of choice and has a much lower incidence of side effects (e.g. such as heparin‐induced thrombocytopaenia, allergic reactions and osteoporosis) than unfractionated heparin.